Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2026 08:00 ET | Source: Cerevance, Inc.

Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting

Solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, demonstrated meaningful reductions in daily OFF time and improvements in sleep-related symptoms across two Phase 2 trialsMeeting...
April 08, 2026 08:00 ET | Source: Cerevance, Inc.

Cerevance to Participate in the 25th Annual Needham Virtual Healthcare Conference

BOSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced...
March 10, 2026 08:00 ET | Source: Cerevance, Inc.

Cerevance to Present Phase 2 Trial Results on OFF Time and Sleep‑Related Outcomes with Solengepras in Parkinson’s Disease at AD/PD™ 2026

Post hoc analyses of two Phase 2 trials examine the potential benefits of solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, across Parkinson’s disease populationsPhase 2 adjunctive...
February 23, 2026 08:00 ET | Source: Cerevance, Inc.

Cerevance to Participate in the TD Cowen 46th Annual Health Care Conference

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced participation...
December 05, 2025 21:00 ET | Source: Cerevance, Inc.

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinson’s Disease

Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) Annual MeetingPivotal Phase 3 ARISE trial evaluating solengepras as an...
December 01, 2025 08:00 ET | Source: Cerevance, Inc.

Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference

Cerevance to Participate in RBC Capital Markets 2025 Healthcare Private Company Conference
November 24, 2025 08:00 ET | Source: Cerevance, Inc.

Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting

Cerevance to Highlight Potential of Solengepras in Parkinson’s Disease at the 2025 Parkinson Study Group Annual Meeting
November 17, 2025 08:00 ET | Source: Cerevance, Inc.

Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Cerevance to Participate in the TD Cowen Treatment Advancements in Obesity and Related Disorders Summit
September 22, 2025 08:00 ET | Source: Cerevance, Inc.

Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s Disease at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Cerevance to Present Phase 2 Data on Solengepras in Parkinson’s Disease at the 2025 International Congress of Parkinson's Disease and Movement Disorders
August 12, 2025 08:00 ET | Source: Cerevance, Inc.

Cerevance to Participate in Piper Sandler Virtual CNS Symposium

Cerevance to Participate in Piper Sandler Virtual CNS Symposium